title: Metabolite profiling identifies markers of uremia.
abstract: ESRD is a state of small-molecule disarray. We applied liquid chromatography/tandem mass spectrometry-based metabolite profiling to survey>350 small molecules in 44 fasting subjects with ESRD, before and after hemodialysis, and in 10 age-matched, at-risk fasting control subjects. At baseline, increased levels of polar analytes and decreased levels of lipid analytes characterized uremic plasma. In addition to confirming the elevation of numerous previously identified uremic toxins, we identified several additional markers of ESRD, including dicarboxylic acids (adipate, malonate, methylmalonate, and maleate), biogenic amines, nucleotide derivatives, phenols, and sphingomyelins. The pattern of lipids was notable for a universal decrease in lower-molecular-weight triacylglycerols, and an increase in several intermediate-molecular-weight triacylglycerols in ESRD compared with controls; standard measurement of total triglycerides obscured this heterogeneity. These observations suggest disturbed triglyceride catabolism and/or beta-oxidation in ESRD. As expected, the hemodialysis procedure was associated with significant decreases in most polar analytes. Unexpected increases in several metabolites, however, indicated activation of a broad catabolic program, including glycolysis, lipolysis, ketosis, and nucleotide breakdown. In summary, this study demonstrates the application of metabolite profiling to identify markers of ESRD, provide perspective on uremic dyslipidemia, and broaden our understanding of the biochemical effects of hemodialysis.
authors.affiliation: Massachusetts General Hospital, 149 13th Street, 8th Floor, Boston, MA, USA.
authors.forename: Eugene P
authors.initials: EP
authors.lastname: Rhee
authors.forename: Amanda
authors.initials: A
authors.lastname: Souza
authors.forename: Laurie
authors.initials: L
authors.lastname: Farrell
authors.forename: Martin R
authors.initials: MR
authors.lastname: Pollak
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Lewis
authors.forename: David J R
authors.initials: DJ
authors.lastname: Steele
authors.forename: Ravi
authors.initials: R
authors.lastname: Thadhani
authors.forename: Clary B
authors.initials: CB
authors.lastname: Clish
authors.forename: Anna
authors.initials: A
authors.lastname: Greka
authors.forename: Robert E
authors.initials: RE
authors.lastname: Gerszten
mesh_terms: D000368:Aged; D001679:Biogenic Amines / Q000097:blood; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003998:Dicarboxylic Acids / Q000097:blood; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009711:Nucleotides / Q000097:blood; D010636:Phenols / Q000097:blood; D006435:Renal Dialysis; D013109:Sphingomyelins / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014511:Uremia / Q000097:blood* / Q000209:etiology*
chemical_list: D001679:Biogenic Amines; D015415:Biomarkers; D003998:Dicarboxylic Acids; D009711:Nucleotides; D010636:Phenols; D013109:Sphingomyelins; D014280:Triglycerides